Table 2 Univariate analysis of the relation between preoperative characteristics and survival of 128 patients with pancreatic cancer.
| Clinicopathological variable | n | % | 1 year | 95% CI | 2 year | 95% CI | 5 year | 95% CI | χ2 | p Value |
|---|---|---|---|---|---|---|---|---|---|---|
| CS (%) | CS (%) | CS (%) | ||||||||
| COX‐2 | ||||||||||
| Negative ⩽5% | 82 | 64 | 51 | 40 to 62 | 32 | 22 to 42 | 8 | 2 to 14 | 3.18 | 0.074 |
| Weak 5 to 10% | 16 | 13 | 14 | 0 to 32 | 7 | 0 to 20 | 7 | 0 to 20 | ||
| Moderate 10 to 50% | 27 | 21 | 44 | 26 to 63 | 0 | 0 to 0 | 0 | 0 to 0 | ||
| Strong >50% | 3 | 2 | 33 | 0 to 88 | 33 | 0 to 88 | 33 | 0 to 88 | ||
| COX‐2 | ||||||||||
| ⩽5% | 82 | 64 | 51 | 40 to 62 | 32 | 22 to 42 | 8 | 2 to 14 | 6.4 | 0.011 |
| >5% | 46 | 36 | 34 | 20 to 47 | 5 | 0 to 11 | 5 | 0 to 11 | ||
| Sex | ||||||||||
| Female | 72 | 56 | 45 | 34 to 57 | 23 | 13 to 32 | 7 | 1 to 13 | 0.12 | 0.727 |
| Male | 56 | 44 | 45 | 32 to 58 | 21 | 11 to 32 | 6 | 0 to 13 | ||
| Age (years) | ||||||||||
| ⩽62 | 64 | 50 | 51 | 39 to 63 | 25 | 15 to 36 | 8 | 1 to 15 | 4.1 | 0.042 |
| >62 | 64 | 50 | 39 | 27 to 51 | 19 | 9 to 28 | 6 | 0 to 12 | ||
| Grade of differentiation | ||||||||||
| 1 | 14 | 11 | 79 | 57 to 100 | 43 | 17 to 67 | 29 | 5 to 52 | 15.0 | <0.001 |
| 2 | 77 | 60 | 48 | 36 to 59 | 25 | 15 to 35 | 7 | 1 to 12 | ||
| 3 | 37 | 29 | 27 | 13 to 41 | 8 | 0 to 17 | 0 | 0 to 0 | ||
| TNM stage | ||||||||||
| I | 25 | 20 | 64 | 45 to 83 | 36 | 17 to 55 | 12 | 0 to 25 | 13.6 | <0.001 |
| II | 39 | 30 | 51 | 36 to 67 | 33 | 19 to 48 | 8 | 0 to 16 | ||
| III | 28 | 22 | 41 | 22 to 60 | 19 | 4 to 33 | 7 | 0 to 17 | ||
| IV | 35 | 27 | 26 | 11 to 40 | 3 | 0 to 8 | 0 | 0 to 0 | ||
| Unavailable | 1 | 1 | – | – | – | – | – | – | ||
| Primary tumour (T) | ||||||||||
| T1 | 7 | 5 | 71 | 38 to 100 | 29 | 0 to 62 | 0 | 0 to 0 | 4.0 | 0.045 |
| T2 | 28 | 22 | 46 | 28 to 65 | 32 | 15 to 49 | 11 | 0 to 22 | ||
| T3 | 63 | 49 | 47 | 35 to 59 | 26 | 15 to 37 | 8 | 1 to 15 | ||
| T4 | 29 | 23 | 31 | 14 to 48 | 3 | 3 to 10 | 3 | 3 to 10 | ||
| TX | 1 | 1 | – | – | – | – | – | – | ||
| Regional nodes (N) | ||||||||||
| N0 | 78 | 61 | 55 | 44 to 66 | 28 | 18 to 38 | 8 | 2 to 14 | 2.5 | 0.115 |
| N1 | 34 | 27 | 34 | 19 to 50 | 16 | 4 to 28 | 8 | 1 to 17 | ||
| NX | 11 | 9 | – | – | – | – | – | – | ||
| Distant metastasis (M) | ||||||||||
| M0 | 118 | 92 | 48 | 39 to 57 | 24 | 16 to 32 | 7 | 3 to 12 | 12.5 | <0.001 |
| M1 | 9 | 7 | 11 | 9 to 32 | 0 | 0 to 0 | 0 | 0 to 0 | ||
| MX | 1 | 1 | – | – | – | – | – | – | ||
| Tumour size | ||||||||||
| ⩽2 cm | 19 | 15 | 67 | 46 to 89 | 23 | 3 to 42 | 0 | 0 to 0 | 3.89 | 0.049 |
| 2 to 4 cm | 66 | 52 | 53 | 41 to 65 | 27 | 17 to 38 | 11 | 4 to 19 | ||
| >4 cm | 29 | 23 | 17 | 4 to 31 | 10 | 1 to 21 | 3 | 0 to 10 | ||
| Unavailable | 14 | 11 | – | – | – | – | – | – | ||
| Tumour location | ||||||||||
| Head | 113 | 88 | 47 | 38 to 57 | 24 | 16 to 32 | 8 | 3 to 13 | 4.01 | 0.045 |
| Other location | 13 | 6 | 31 | 6 to 56 | 8 | 0 to 22 | 0 | 0 to 0 | ||
| Curability | ||||||||||
| Intent to cure | 85 | 66 | 57 | 47 to 68 | 32 | 22 to 42 | 10 | 3 to 16 | 23.11 | <0.001 |
| Non‐curative | 43 | 34 | 21 | 9 to 33 | 2 | 2 to 7 | 0 | 0 to 0 |
CI, confidence interval; COX‐2, cyclooxygenase‐2; CS, cumulative survival.